BLFS: Pennystock mit big news mit 30 Billion $ company GLW - 500 Beiträge pro Seite
eröffnet am 31.10.06 16:37:14 von
neuester Beitrag 31.10.06 16:59:59 von
neuester Beitrag 31.10.06 16:59:59 von
Beiträge: 3
ID: 1.091.265
ID: 1.091.265
Aufrufe heute: 0
Gesamt: 1.187
Gesamt: 1.187
Aktive User: 0
ISIN: US09062W2044 · WKN: A1XCF2 · Symbol: BJX1
17,300
EUR
+2,37 %
+0,400 EUR
Letzter Kurs 07.05.24 Tradegate
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
2,4000 | +49,07 | |
1,1600 | +40,52 | |
1,3670 | +25,30 | |
1,0340 | +23,54 | |
6,7100 | +22,00 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,5000 | -13,79 | |
1,3800 | -20,80 | |
0,6700 | -26,58 | |
2,1300 | -34,41 | |
3,1600 | -38,64 |
Noch unentdeckt heute. Könnte durchaus im Laufe des Tages noch richtig laufen. Würde aber nur kleine Positionen kaufen
BioLife Solutions Incorporated and Corning Incorporated Announce Increased Cell Performance Through Product Combination
Tuesday October 31, 8:30 am ET
Corning(R) CellBIND(R) Surface Used With BioLife Solutions' CryoStor(TM) Offers 58-Percent Increase in 24-Hour Post-Preservation Cell Survival
CORNING, N.Y.--(BUSINESS WIRE)--BioLife Solutions Inc. (OTC Bulletin Board: BLFS - News), a leading manufacturer of proprietary cryopreservation solutions for cells and tissue preservation, and Corning Incorporated (NYSE: GLW - News) today announced the publication of a report that describes the benefits of the combination of the BioLife CryoStor(TM) CS5 with Corning's CellBIND® Surface. The integration of these complementary technologies resulted in a significant increase in the survival and attachment of LNCaP cells as compared to traditional solutions and tissue culture treated (TCT) surfaces. The CryoStor/Corning CellBIND Surface combined approach offers a distinct advantage to the pharmaceutical, drug discovery, and toxicity testing industries by enabling researchers to reduce time and effort presently required to collect, store, retrieve and utilize high-quality cryopreserved cells. This thereby increases productivity and cost-effectiveness of in vitro screening processes.
"This validation of serum-free and protein-free CryoStor provides an important endorsement of our preservation technology platform and intellectual property portfolio," said Mike Rice, chief executive officer, BioLife Solutions. "The study jointly performed by Corning and BioLife scientists demonstrates fundamental advantages that the combined products offer to a broad industry base, including drug discovery and cellular therapy."
Data from independent experiments showed that the Cryostor solution and Corning CellBIND surface product combination offered a 58-percent increase in post-preservation cell survival when compared to traditional tissue culture surface and serum and protein based freezing media. "It's important to note that cell survival was measured 24 hours post-thaw, a much more relevant performance metric than immediate post-thaw survival measurement, which often gives researchers a false sense of practical cell function and viability," added John G. Baust, PhD, chief scientific officer, BioLife Solutions.
"These independently verified results confirm the benefits of using the Corning CellBIND surface combined with the protein-free BioLife CryoStorCS5 freezing solution to improve the survival of LNCaP cells," said Mark Beck, vice president and general manager, Corning Life Sciences. "Our relationship with BioLife further demonstrates our commitment to developing innovative technologies and/or partnering with industry leaders to provide our global customers with the solutions and expertise they require to improve performance and results."
The report, titled "Enhanced Survival of LNCaP Cells Following Cryopreservation Using the CryoStor CS5 Preservation Solutions and Corning CellBIND Surface," was co-authored by Corning Life Sciences and BioLife Solutions scientists and will appear in an upcoming issue of Genetic Engineering News. Additionally, a Corning application note (SnAPPShot) on the performance results can be accessed by visiting the following link on the Corning website:
http://www.corning.com/lifesciences/technical_information/te… /snappshots_084_lncap_cryostor_cellbind.pdf.
BioLife Solutions Incorporated and Corning Incorporated Announce Increased Cell Performance Through Product Combination
Tuesday October 31, 8:30 am ET
Corning(R) CellBIND(R) Surface Used With BioLife Solutions' CryoStor(TM) Offers 58-Percent Increase in 24-Hour Post-Preservation Cell Survival
CORNING, N.Y.--(BUSINESS WIRE)--BioLife Solutions Inc. (OTC Bulletin Board: BLFS - News), a leading manufacturer of proprietary cryopreservation solutions for cells and tissue preservation, and Corning Incorporated (NYSE: GLW - News) today announced the publication of a report that describes the benefits of the combination of the BioLife CryoStor(TM) CS5 with Corning's CellBIND® Surface. The integration of these complementary technologies resulted in a significant increase in the survival and attachment of LNCaP cells as compared to traditional solutions and tissue culture treated (TCT) surfaces. The CryoStor/Corning CellBIND Surface combined approach offers a distinct advantage to the pharmaceutical, drug discovery, and toxicity testing industries by enabling researchers to reduce time and effort presently required to collect, store, retrieve and utilize high-quality cryopreserved cells. This thereby increases productivity and cost-effectiveness of in vitro screening processes.
"This validation of serum-free and protein-free CryoStor provides an important endorsement of our preservation technology platform and intellectual property portfolio," said Mike Rice, chief executive officer, BioLife Solutions. "The study jointly performed by Corning and BioLife scientists demonstrates fundamental advantages that the combined products offer to a broad industry base, including drug discovery and cellular therapy."
Data from independent experiments showed that the Cryostor solution and Corning CellBIND surface product combination offered a 58-percent increase in post-preservation cell survival when compared to traditional tissue culture surface and serum and protein based freezing media. "It's important to note that cell survival was measured 24 hours post-thaw, a much more relevant performance metric than immediate post-thaw survival measurement, which often gives researchers a false sense of practical cell function and viability," added John G. Baust, PhD, chief scientific officer, BioLife Solutions.
"These independently verified results confirm the benefits of using the Corning CellBIND surface combined with the protein-free BioLife CryoStorCS5 freezing solution to improve the survival of LNCaP cells," said Mark Beck, vice president and general manager, Corning Life Sciences. "Our relationship with BioLife further demonstrates our commitment to developing innovative technologies and/or partnering with industry leaders to provide our global customers with the solutions and expertise they require to improve performance and results."
The report, titled "Enhanced Survival of LNCaP Cells Following Cryopreservation Using the CryoStor CS5 Preservation Solutions and Corning CellBIND Surface," was co-authored by Corning Life Sciences and BioLife Solutions scientists and will appear in an upcoming issue of Genetic Engineering News. Additionally, a Corning application note (SnAPPShot) on the performance results can be accessed by visiting the following link on the Corning website:
http://www.corning.com/lifesciences/technical_information/te… /snappshots_084_lncap_cryostor_cellbind.pdf.
Dann schau dir mal Biocurex (BOCX.OB)an,die könnte nicht nur,die ist heute angesprungen. AKT +12,16%
Antwort auf Beitrag Nr.: 25.039.400 von nekro am 31.10.06 16:56:24Dann pass nur auf, dass Du vor verkaufst bevor Lebed den Stecker rauszieht....
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+1,01 | |
+0,39 | |
+1,15 | |
+0,48 | |
-2,49 | |
+2,06 | |
0,00 | |
-0,55 | |
-0,12 | |
+0,65 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
318 | ||
130 | ||
117 | ||
103 | ||
73 | ||
58 | ||
47 | ||
45 | ||
45 | ||
44 |